Sector: Health Care
Director information for OMNIAB INC (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Carolyn Bertozzi, Ph.D. | Chair, Science and Technology Committee | [] | ["Science and Technology Committee"] | 2026 | |
| CAROLYN R. BERTOZZI, Ph.D. | Director; Anne T. and Robert M. Bass Professor of Chemistry | 59 | ["Anne T. and Robert M. Bass Professor of Chemistry at Stanford University","Professor of Chemical and Systems Biology and Radiology","Investigator at the Howard Hughes Medical Institute","Former Director of the Molecular Foundry at Lawrence Berkeley National Laboratory","Professor of Chemistry and Molecular and Cell Biology at the University of California, Berkeley","Board member of Eli Lilly, Acepodia, and Xaira Therapeutics","Nobel Prize in Chemistry (2022)","Wolf Prize in Chemistry (2022)","Founder of multiple biotechnology start-ups","Bertozzi Ph.D.","Professor of Chemical and Systems Biology","Radiology","Baker Family Co-Director of Sarafan ChEM-H"] | ["Human Capital Management and Compensation","Science and Technology (Chair)","Human Capital Management and Compensation (\"HCMC\") Committee","Science and Technology Committee Chair"] | 2026 |
| JENNIFER COCHRAN, Ph.D. | Director; Macovski Professor of Bioengineering and Vice President for SLAC National Linear Accelerator Laboratory and for Strategic Initiatives, Stanford University; Member, Science and Technology Committee | 54 | ["Addie and Al Macovski Professor of Bioengineering at Stanford University","Vice President for SLAC National Linear Accelerator Laboratory and for Strategic Initiatives","Founding member of the Stanford Bioengineering Department","Former Chair of Stanford Bioengineering Department","Senior Associate Vice Provost of Research at Stanford","Co-founded Red Tree Venture Capital","Former Chief Scientist of Lagunita Biosciences","Board experience with several biotechnology companies","Macovski Professor of Bioengineering","Vice President for SLAC National Linear Accelerator Laboratory","Strategic Initiatives, Stanford University"] | ["Nominating and Corporate Governance","Science and Technology","Nominating and Corporate Governance (\"NCG\") Committee Chair","Science and Technology Committee"] | 2026 |
| John Higgins | Former Chief Executive Officer of Ligand Pharmaceuticals Incorporated; Chairman of the Board | 56 | ["Former CEO of Ligand Pharmaceuticals","Director and Chief Executive Officer at Ligand Pharmaceuticals Incorporated from January 2007 to December 2022","Chief Financial Officer at Connetics Corporation since 1997","Executive Vice President, Finance and Administration and Corporate Development at Connetics until acquisition","Member of the executive management team at BioCryst Pharmaceuticals Inc.","Member of the healthcare banking team of Dillon, Read & Co. Inc.","Serves on the board of directors of Bio-Techne Corporation","Trustee of the Walker Art Center","Has served as a director on numerous public and private companies","Graduated Magna Cum Laude from Colgate University with an A.B. in economics"] | ["Board Chair","Audit Committee","NCG Committee","Audit","Nominating and Corporate Governance"] | 2026 |
| Matthew W. Foehr | President and CEO of OmniAb, Inc.; President, Chief Executive Officer and Director | 53 | ["President and CEO of OmniAb, Inc.","More than 25 years of pharmaceutical industry experience","Former President and Chief Operating Officer at Ligand Pharmaceuticals","Previous roles at GlaxoSmithKline and Stiefel Laboratories","Board member of Viking Therapeutics, Inc."] | [] | 2026 |
| PHILIP J. GOTWALS, Ph.D. | Director; Partner, RedSky Partners, LLC; Member, Science and Technology Committee | 63 | ["30 years of biopharmaceutical experience in R&D, business development, product development and therapeutic area strategy","Global Head of Business Development and Licensing at Novartis Institutes for BioMedical Research","Executive Director, Oncology/Immuno-Oncology Research at NIBR","Vice President, Program Management at Altus Pharmaceuticals","Senior Director at Biogen Idec","Partner at RedSky Partners, LLC","Board member of Capricor Therapeutics, Inc.","B.A. in biology from Amherst College","Ph.D. in genetics from the University of California at Berkeley","Postdoctoral research at MIT","Business training at Harvard Business School"] | ["Human Capital Management and Compensation","Science and Technology","HCMC Committee","Science and Technology Committee"] | 2026 |
| Steve Crouse | Senior Vice President, Bio-Techne Corporation; Director; Member, Science and Technology Committee | 53 | ["Senior Vice President, Bio-Techne Corporation","Over 20 years of experience in research and development, business development, and general management","Senior Vice President and General Manager of the Analytical Solutions Division at Bio-Techne Corporation since March 2021","Senior Director and General Manager of the Protein Detection and Quantification unit at Thermo Fisher Scientific Inc. from June 2018 to March 2021","Chief Operating Officer at Vortex Biosciences, Inc.","Senior Vice President of Sales and Marketing at Freeslate Inc.","Leadership roles at Bio-Rad Laboratories and Invitrogen Corporation","B.S. in pharmacology from the University of California, Santa Barbara","M.S. in biochemistry from Georgetown University","M.B.A. from the Marshall School of Business at the University of Southern California"] | ["Audit Committee","Science and Technology Committee","Audit","Science and Technology"] | 2026 |
| STEVE LOVE | Director; Former CFO of Sift Science, Inc. | 57 | ["Chief Financial Officer of Sift Science, Inc.","Chief Financial Officer at Heap Inc.","Chief Financial Officer at Juniper Square Inc.","Chief Financial Officer at Dialpad, Inc.","Over 30 years in finance","Formerly at Ernst & Young LLP","Former CFO of Sift Science, Inc."] | ["Audit","Human Capital Management and Compensation","Audit Committee Chair","HCMC Committee Chair"] | 2026 |
